Thyrotoxicosis, typically preceding hypothyroidism, has a lower incidence estimated at 0.2–5.2% (anti-CTLA4), 0.6–3.7% (anti-PD1/PDL1), and 8.0–11.1% (combination treatment) (56). Here, CTLA4 is linked to thyrotoxicosis.